Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

An effective and safe targeted therapy for treatment of Myasthenia gravis

Descripción del proyecto

Tecnología de tolerancia innovadora para el tratamiento de enfermedades autoinmunitarias

La miastenia grave (MG) es una de las enfermedades neuromusculares autoinmunitarias crónicas más comunes y provoca debilidad en los músculos esqueléticos responsables de la respiración y del movimiento de distintas partes del cuerpo. Actualmente no existe ninguna cura para la MG, que es una enfermedad huérfana (rara) con una necesidad médica insatisfecha. Toleranzia es una empresa farmacéutica sueca que desarrolla terapias dirigidas a los propios recursos del sistema inmunitario para tratar enfermedades autoinmunitarias. En el marco del proyecto TOL2, financiado con fondos europeos, la empresa abordará la necesidad de desarrollar un tratamiento eficaz y seguro para curar la MG. La tecnología de tolerancia que subyace al proyecto TOL2 podría emplearse para tratar otras enfermedades autoinmunitarias.

Objetivo

Myasthenia gravis (MG) is a rare disease affecting 2/10.000 people. Although being a rare disease, MG is the most common chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles, which are responsible for breathing and moving parts of the body, including the arms and legs. MG restricts patients from having a full participation in everyday activities, frequently leading to unemployment and reducing their quality of life. Many patients may eventually experience a myasthenic crisis, the treatment of which is very expensive. Such crises can lead to the death of the patient. There is currently no cure for MG and neither is there any cure in sight. Even though there are over 30 MG-related clinical trials currently in progress, most of them are only symptomatic treatments.

Considering this urgent medical need, we are developing TOL2, an innovative therapy with potential to cure MG (not only symptomatic treatment). This will be the first therapy for MG that induces long-term remission. TOL2 is based on a tolerance-technology with potential to be developed for treatment of other autoimmune diseases. TOL2 has been granted Orphan Drug Designation by the US FDA.

Toleranzia is a Swedish pharmaceutical research and development company. Our therapies utilize the immune system’s own intrinsic power to treat autoimmune diseases. Our mission is to develop innovative therapies that will cure autoimmune diseases.

Our business strategy for TOL2 is to complete clinical phase IIa, and then to look for an agreement with a global pharma partner, who can or co-develop the therapy. Under this business model, revenue streams are obtained through upfront payments, milestone payments and royalties on product sales.

Considering total project cost of €5,6 m during years 2019-2021, upfront payments above €14 m and 20% royalties over sales, the NPV of the investment calculated (WACC 10%) will surpass €257m by 2029.

Ámbito científico (EuroSciVoc)

Programa(s)

Tema(s)

Régimen de financiación

SME-1 - SME instrument phase 1

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) H2020-EIC-SMEInst-2018-2020

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

TOLERANZIA AB
Aportación neta de la UEn
€ 50 000,00
Dirección
ERIK DAHLBERGSGATAN 11 A
411 26 Goteborg
Suecia
Pyme
Sí
Región
Södra Sverige Västsverige Västra Götalands län
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 71 429,00